Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLR Allarity Therapeutics Inc

Pre-Mkt 05-14 08:41:13 EDT

1.54

+0.02

+1.32%

盘前1.54

+0.000.00%

08:38 EDT

High1.59	Low1.51	Vol100.89K
Open1.55	D1 Closing1.52	Amplitude5.26%
Mkt Cap24.36M	Tradable Cap24.32M	Total Shares15.82M
T/O155.55K	T/O Rate0.64%	Tradable Shares15.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALLR","market":"US","secType":"STK","nameCN":"Allarity Therapeutics Inc","latestPrice":1.54,"timestamp":1778702400000,"preClose":1.52,"halted":0,"volume":100887,"hourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.54,"latestTime":"08:38 EDT","volume":3625,"amount":5792.7713875,"timestamp":1778762323762,"change":0,"changeRate":0,"amplitude":0.065779},"delay":0,"changeRate":0.013157894736842117,"floatShares":15794100,"shares":15818980,"eps":-0.78,"marketStatus":"Pre-Mkt","change":0.02,"latestTime":"05-14 08:41:13 EDT","open":1.55,"high":1.59,"low":1.51,"amount":155547.5059791,"amplitude":0.052632,"askPrice":1.63,"askSize":2626,"bidPrice":1.5,"bidSize":115,"shortable":3,"etf":0,"ttmEps":-0.78,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778765400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.54,"preHourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.54,"latestTime":"08:38 EDT","volume":3625,"amount":5792.7713875,"timestamp":1778762323762,"change":0,"changeRate":0,"amplitude":0.065779},"postHourTrading":{"tag":"盘后","latestPrice":1.54,"preClose":1.54,"latestTime":"19:41 EDT","volume":45,"amount":70.0358,"timestamp":1778715692181,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.255698363558346},"requestUrl":"/m/hq/s/ALLR","defaultTab":"news","newsList":[{"id":"2634234359","title":"Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634234359","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634234359?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:21","pubTimestamp":1778527317,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics named Jesper Hoeiland as a director in an initial Form 3 filing dated June 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3HP1BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633745995","title":"Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633745995","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633745995?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244313,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics CEO Thomas Jensen to speak at Precision Medicine Forum Europe 2026 in Stockholm on May 11-12, 2026.On May 11, Jensen scheduled to present “Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical Trials” from 10:20-10:40 CEST in oncology track.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL86JlnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4139","IE00BN0W2W23.USD","LU2095319765.USD","ALLR","SG9999014005.SGD","LU2210150020.SGD","BK4585","SG9999014021.USD","BK4112","NDAQ","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142171","title":"Allarity Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142171","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142171?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:32","pubTimestamp":1778157148,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Allarity Therapeutics Inc ALLR.OQ ALLR.O is expected to  report results for the period ending March 31 2026LSEG'","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633567910","title":"Allarity says Phase 3 stenoparib manufacturing campaign stays on track for Q3 2026 completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2633567910","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633567910?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:02","pubTimestamp":1777982561,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics advanced stenoparib toward pivotal development by moving ahead with a Phase 3 manufacturing campaign, targeting completion no later than Q3 2026.No new clinical results were presented; program positioning draws on previously reported data indicating longer survival in advanced, platinum-resistant ovarian cancer.Manufacturing timeline is intended to support an expected pivotal trial in advanced ovarian cancer, aligning with FDA Fast Track status aimed at speeding a potential approval path.All manufacturing-related payments have been completed, removing expected near-term cash outlays tied to this supply build.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL56ypx7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","NDAQ","LU2210149790.SGD","BK4588","ALLR","BK4139","SG9999014013.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630392574","title":"Allarity receives notice of allowance from USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2630392574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630392574?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:21","pubTimestamp":1777296062,"startTime":"0","endTime":"0","summary":"Allarity (ALLR) announced that the United States Patent and Trademark Office has issued a notice of allowance for its patent application covering t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-receives-notice-of-allowance-from-uspto-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-receives-notice-of-allowance-from-uspto-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630257396","title":"Allarity Therapeutics Inc - Patent Expected to Be Formally Granted Within Three Months, Subject to Standard Administrative Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2630257396","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630257396?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:07","pubTimestamp":1777291638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A0PY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396110","title":"Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396110","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396110?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281537/0/en/Allarity-Therapeutics-Announces-that-the-Stenoparib-DRP-Test-Has-Received-a-Notice-of-Allowance-from-the-US-Patent-and-Trademark-Office.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ALLR","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629036738","title":"Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036738","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036738?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:05","pubTimestamp":1776773151,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics published two posters for presentation at AACR Annual Meeting 2026 in San Diego on April 17-22.One poster reports results already presented linking higher stenoparib DRP scores with longer overall survival in a Phase 2 ovarian cancer trial of stenoparib.Another poster to be presented April 21 outlines preclinical findings that stenoparib can modulate WNT signaling and curb growth in colorectal cancer cell lines at clinically relevant exposures.Update positions stenoparib as a differentiated oral candidate in colorectal cancer while supporting DRP-based patient selection as a strategy to improve outcomes in ovarian cancer development.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL8jQW9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2W23.USD","LU2095319765.USD","LU2210149790.SGD","BK4139","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","IE00BN0W2V16.EUR","BK4585","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014039.USD","SG9999014005.SGD","SG9999014021.USD","SG9999014013.SGD","NDAQ","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626174143","title":"Allarity Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626174143","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626174143?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:19","pubTimestamp":1775855991,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics scheduled 2026 annual shareholder meeting for June 26, 2026 in virtual format.Shareholders will vote to elect Class I director nominee Jesper Hoiland to a term ending at 2029 annual meeting.Ballot includes proposal to expand 2021 equity incentive plan share pool to 2,021,990 shares from 1,521,990 shares.Meeting agenda also includes advisory vote on executive pay, approval to issue additional common shares under Tumim Stone Capital purchase agreement, plus amendment to limit liability of certain officers.Shareholders will also vote on auditor appointment ratification for fiscal 2026, plus authority to adjourn meeting to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL4xdtBg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623757581","title":"BRIEF-Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2623757581","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623757581?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:48","pubTimestamp":1774961289,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate ProgressAllarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE PROGRESSSource text: ID:nGNX55ZlGYFurther company coverage: ALLR.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA9L1FSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324559","title":"Allarity FY25 net loss narrows to $11 million; revenue rises to $0.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324559?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:31","pubTimestamp":1774906299,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics posted net loss of $11.2 million for fiscal 2025, narrowing from $24.5 million a year earlier.Revenue was $0.3 million, compared with no revenue in 2024.Operating loss tightened to $12.6 million on total operating costs and expenses of $12.9 million.Cash ended 2025 at $14.7 million, while cash used in operating activities was $14.8 million.Allarity said it is now focused on stenoparib and its companion diagnostic, expecting current cash to fund operations for at least the next 12 months from the date of the annual report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8757wX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622465822","title":"Allarity Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622465822","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622465822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:33","pubTimestamp":1774618389,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Allarity Therapeutics Inc ALLR.OQ ALLR.O is expected to  report resultson March 31 (estimated) for the period en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680042","title":"Allarity Therapeutics Closes $20 Million Non-Convertible Debt Financing With Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680042","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680042?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:01","pubTimestamp":1772802073,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics said it closed a $20 million non-convertible debt financing with Streeterville Capital through a note purchase agreement. The company issued two promissory notes with original principal amounts of $10.93 million and $10.0 million, and said the proceeds are expected to extend its cash runway into summer 2028 and support completion of its Phase 2 ovarian cancer trial and advancement of stenoparib toward pivotal development and commercialization.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL9yWsZn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","ALLR","BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014021.USD","BK4139","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","BK4112","NDAQ","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617213680","title":"BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2617213680","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617213680?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:01","pubTimestamp":1772802063,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And CommercializationMarch 6 (Reuters) - Allarity Therapeutics Inc ALLR.O:ALLARITY ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA9BJ2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617802496","title":"Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802496?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA9BJ2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612944501","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Relapsed SCLC Trial of Stenoparib Plus Temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2612944501","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612944501?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420528,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. reported that the first patients have been dosed in a U.S. Department of Veterans Affairs-funded, investigator-initiated Phase 2 trial evaluating stenoparib , a dual PARP and WNT pathway inhibitor, in combination with temozolomide for relapsed small cell lung cancer. The study is open for enrollment across 11 VA medical centers in the United States. No clinical results were presented in the announcement; results are expected to be reported in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL15vmqR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139","BK4588","LU2210149790.SGD","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","BK4585","SG9999014039.USD","BK4112","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","ALLR","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612446649","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446649","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446649?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420500,"startTime":"0","endTime":"0","summary":"Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240189/0/en/Allarity-Therapeutics-Doses-First-Patients-in-VA-Funded-Phase-2-Trial-Focused-on-Small-Cell-Lung-Cancer-with-High-Unmet-Need.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","ALLR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611908289","title":"Allarity Therapeutics Inc - Prospectus for Resale of 255,103 Shares of Common Stock by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611908289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611908289?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:38","pubTimestamp":1770932328,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z81NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608987871","title":"Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987871?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:20","pubTimestamp":1770124833,"startTime":"0","endTime":"0","summary":"Allarity (ALLR) Therapeutics announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608879859","title":"Allarity Therapeutics Announces That Its Collaborative Phase 2 Trial With the United States Veteran’s Administration Combining Stenoparib With Temozolomide in Relapsed Small Cell Lung Cancer Is NOW Open for Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879859?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123652,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allarity.com","stockEarnings":[{"period":"1week","weight":0.0405},{"period":"1month","weight":0.2941},{"period":"3month","weight":0.8218},{"period":"6month","weight":0.3051},{"period":"1year","weight":0.4808},{"period":"ytd","weight":0.4259}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.137955},{"month":2,"riseRate":0,"avgChangeRate":-0.233915},{"month":3,"riseRate":0.4,"avgChangeRate":-0.236538},{"month":4,"riseRate":0.4,"avgChangeRate":-0.249609},{"month":5,"riseRate":0.4,"avgChangeRate":-0.045493},{"month":6,"riseRate":0.25,"avgChangeRate":-0.349039},{"month":7,"riseRate":0.25,"avgChangeRate":-0.205374},{"month":8,"riseRate":0.25,"avgChangeRate":0.045342},{"month":9,"riseRate":0.25,"avgChangeRate":-0.31064},{"month":10,"riseRate":0,"avgChangeRate":-0.290985},{"month":11,"riseRate":0,"avgChangeRate":-0.125579},{"month":12,"riseRate":0.25,"avgChangeRate":-0.118424}],"exchange":"NASDAQ","name":"Allarity Therapeutics Inc","nameEN":"Allarity Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allarity Therapeutics Inc,ALLR,Allarity Therapeutics Inc股票,Allarity Therapeutics Inc股票老虎,Allarity Therapeutics Inc股票老虎国际,Allarity Therapeutics Inc行情,Allarity Therapeutics Inc股票行情,Allarity Therapeutics Inc股价,Allarity Therapeutics Inc股市,Allarity Therapeutics Inc股票价格,Allarity Therapeutics Inc股票交易,Allarity Therapeutics Inc股票购买,Allarity Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction